| Christopher Fraser Fritzsche, MD | |
|
3208 Oleander Dr, Wilmington, NC 28403-0800 | |
| (910) 794-3929 | |
| (910) 798-2303 |
| Full Name | Christopher Fraser Fritzsche |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 3208 Oleander Dr, Wilmington, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700048410 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD.207660 (Louisiana) | Primary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 2013-00738 (North Carolina) | Secondary |
| Entity Name | Administrators Of The Tulane Educational Fund |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528014164 PECOS PAC ID: 0446163760 Enrollment ID: O20031201000636 |
News Archive
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.
Fears about rationing are a hot-button issue in the health care debate, but some health experts argue that the U.S. system already faces rationing. Others point out that the U.S. may look to Europe for examples of how private-market systems can cost less without raising concerns of rationing care.
Volcano Corporation said today that the Superior Court of Massachusetts has issued a decision that ruled in favor of Volcano and its wholly-owned subsidiary Axsun Technologies, Inc., and against LightLab Imaging, Inc., on all of LightLab's remaining claims for trade secret misappropriation. The 11-page decision also rejected LightLab's request for injunctive relief.
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.
› Verified 3 days ago
| Entity Name | East Louisiana State Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043206543 PECOS PAC ID: 6002853835 Enrollment ID: O20050413000902 |
News Archive
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.
Fears about rationing are a hot-button issue in the health care debate, but some health experts argue that the U.S. system already faces rationing. Others point out that the U.S. may look to Europe for examples of how private-market systems can cost less without raising concerns of rationing care.
Volcano Corporation said today that the Superior Court of Massachusetts has issued a decision that ruled in favor of Volcano and its wholly-owned subsidiary Axsun Technologies, Inc., and against LightLab Imaging, Inc., on all of LightLab's remaining claims for trade secret misappropriation. The 11-page decision also rejected LightLab's request for injunctive relief.
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.
› Verified 3 days ago
| Entity Name | Childrens Hospital Medical Practice Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821090713 PECOS PAC ID: 5597944579 Enrollment ID: O20110124000073 |
News Archive
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.
Fears about rationing are a hot-button issue in the health care debate, but some health experts argue that the U.S. system already faces rationing. Others point out that the U.S. may look to Europe for examples of how private-market systems can cost less without raising concerns of rationing care.
Volcano Corporation said today that the Superior Court of Massachusetts has issued a decision that ruled in favor of Volcano and its wholly-owned subsidiary Axsun Technologies, Inc., and against LightLab Imaging, Inc., on all of LightLab's remaining claims for trade secret misappropriation. The 11-page decision also rejected LightLab's request for injunctive relief.
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Fraser Fritzsche, MD 1430 Tulane Ave, # 8448, New Orleans, LA 70112-2632 Ph: (504) 988-5405 | Christopher Fraser Fritzsche, MD 3208 Oleander Dr, Wilmington, NC 28403-0800 Ph: (910) 794-3929 |
News Archive
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.
Fears about rationing are a hot-button issue in the health care debate, but some health experts argue that the U.S. system already faces rationing. Others point out that the U.S. may look to Europe for examples of how private-market systems can cost less without raising concerns of rationing care.
Volcano Corporation said today that the Superior Court of Massachusetts has issued a decision that ruled in favor of Volcano and its wholly-owned subsidiary Axsun Technologies, Inc., and against LightLab Imaging, Inc., on all of LightLab's remaining claims for trade secret misappropriation. The 11-page decision also rejected LightLab's request for injunctive relief.
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.
› Verified 3 days ago
Dr. James Perry Mayo Iii, M.D., MPH Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1426 Navaho Trl Unit 107, Wilmington, NC 28409 Phone: 910-518-8807 Fax: 910-216-4278 | |
Dr. Christopher Robert Myers, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3208 Oleander Dr, Wilmington, NC 28403 Phone: 910-794-3929 Fax: 910-798-2303 | |
Dr. Lionel Gregory Fernando, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 5617 Maxwell Pl, Wilmington, NC 28409 Phone: 910-742-9243 Fax: 888-746-1787 | |
Nina Leah Yokochi-funkhouser, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2131 S 17th St, Wilmington, NC 28401 Phone: 910-815-5830 | |
Chih-cheng Frank Chen, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1608 Wellington Avenue, Wilmington Neurology Clinic, Wilmington, NC 28401 Phone: 910-395-5521 Fax: 910-350-1123 | |
Dr. Burt Powers Johnson, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2023 S 17th St, Wilmington, NC 28401 Phone: 910-251-6499 Fax: 910-251-6511 | |
Dr. Brett A Gurkin, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3208 Oleander Dr, Wilmington, NC 28403 Phone: 910-794-3929 Fax: 910-798-2303 |